Firm unveils drug-eluting catheter
HRT 'still acceptable for menopausal symptoms'
NICE developing a series of rapid COVID-19 guidelines
New programme reduces C. diff
UK health chiefs vow to stamp out MRSA
Smart infusion pumps: Role in safe drug administration
A device that allows for the release of drugs to treat arterial disease has been launched.
The IN.PACT Amphirion paclitaxel-eluting PTA balloon catheter from Invatec is designed specifically to treat atherosclerosis in arteries located below the knee.
The device uses Invatec coating FreePac, which aids in the absorption of paclitaxel molecules into the artery wall.
Co-founders of Invatec, Andrea Venturelli and Stefan Widensohler said: "According to research published in the New England Journal of Medicine and Circulation, drug-eluting balloons utilising a special drug-elution formulation have demonstrated effectiveness in the treatment of atherosclerosis and the prevention of restenosis.
"Invatec is taking this approach further by offering a drug elution therapy targeted specifically for below-the-knee interventions and placing it on a market-leading, state-of-the-art platform, the Amphirion Deep balloon catheter."
Dr Ulrich Speck and Dr Bruno Scheller, who pioneered drug-eluting balloon therapy, said it has the potential of cutting the need for follow-up treatments in patients with atherosclerosis.
Impaired blood flow caused by blockages below the knee can result in pain, poor wound healing, gangrene and a high risk of death.
Invatec
Nano-tech firm develops micro pump
Aegate takes on counterfeit drugs
Hard lessons and small victories in patient safety
Sorafenib and hepatocellular carcinoma
Improving the safety of emergency oxygen therapy